ArticleBMC endocrine disorders2025
Association between hs-CRP/HDL-C ratio and risk of prediabetes or diabetes: a cross-sectional study based on NHANES 2015-2023.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- hs-CRP/HDL Ratio Across Obesity and Type 2 Diabetes Mellitus Phenotypes in Adults: A Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2026Article
- Inflammation and Cardiovascular Risk: A Systematic Review of High-Sensitivity CRP as a Prognostic Indicator.Cureus · 2026Review
- The high-sensitivity C-reactive protein-to-high-density lipoprotein cholesterol ratio as a novel composite biomarker for predicting 28-day all-cause mortality in sepsis: a retrospective cohort study.Frontiers in medicine · 2026Article
- Article
- Integrating Serum Lipid Biomarkers Into Machine Learning for the Differential Diagnosis of Breast Nodules.The breast journal · 2026Article
- Remnant Cholesterol Inflammatory Index and New-Onset Diabetes in Middle-Aged and Older Adults: Evidence From Prospective Surveys of Chinese and UK Populations.Journal of diabetes research · 2025Article
- Association of Atherogenic Combined Index, hs-CRP/HDL-C Ratio, and TC/HDL-C-BMI Index with Low Vitamin D Levels among PLWH on Antiretroviral Therapy: A Cross-Sectional Study in Southwestern Uganda.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe hs-CRP/HDL-C ratio is a novel marker reflecting inflammation and lipid metabolism disorders, but systematic investigations regarding its association with prediabetes and diabetes are still lacking. This study aimed to explore the association between the hs-CRP/HDL-C ratio and the presence of prediabetes and diabetes, thereby providing a theoretical basis for identifying individuals with dysglycemia at an earlier stage.
methodsA total of 18,472 eligible adult participants were included based on NHANES data from 2015 to 2023. The hs-CRP/HDL-C ratio was divided into quartiles, and its association with the odds of prediabetes and diabetes was evaluated using multivariable logistic regression and restricted cubic spline (RCS) analysis. Subgroup analyses were performed to explore the predictive value of the ratio across different population subgroups. All statistical analyses were weighted to enhance the representativeness of the findings.
resultsA significant positive association was observed between the hs-CRP/HDL-C ratio and the odds of prediabetes and diabetes. Compared to individuals with normal glucose levels, those with prediabetes and diabetes had significantly elevated hs-CRP/HDL-C ratios (both p < 0.001). An increasing trend in the prevalence of prediabetes and diabetes was observed with rising hs-CRP/HDL-C ratio (28.72-44.10% and 4.38-17.34%, respectively). In Model 3, after full adjustment, each unit increase in the hs-CRP/HDL-C ratio was associated with a 13.3% higher odds of prediabetes (OR = 1.133, 95% CI: 1.082-1.184, p < 0.001) and a 26.9% higher odds of diabetes (OR = 1.269, 95% CI: 1.186-1.351, p < 0.001). The RCS analysis revealed a significant nonlinear association between the hs-CRP/HDL-C ratio and the risks of prediabetes and diabetes, with apparent inflection points near 0.614 and 1.168 (Model 3). Additionally, receiver operating characteristic (ROC) analysis showed that the hs-CRP/HDL-C ratio had better discriminatory performance than either hs-CRP or HDL-C alone in predicting prediabetes (AUC = 0.751) and diabetes (AUC = 0.857). Subgroup analyses further demonstrated notable heterogeneity in the predictive value of this indicator across various demographic and clinical strata.
conclusionOur findings suggest that the hs-CRP/HDL-C ratio is significantly associated with the presence of prediabetes and diabetes in a nonlinear dose-response pattern, indicating its potential as a marker associated with glycemic disorders. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.